Seeking Alpha

Curtisayee

Curtisayee
Send Message
View as an RSS Feed
View Curtisayee's Comments BY TICKER:
Latest  |  Highest rated
  • Celladon: CUPID-2 Is Likely To Fail [View article]
    Author nailed it! Nice work. Now about QURE...
    Apr 26, 2015. 05:04 PM | 4 Likes Like |Link to Comment
  • InVivo Revolutionizing Spinal Cord Injury [View article]
    From an investors standpoint, this is both a safety AND efficacy trial. It's a device, not a drug, so there is no dosage change to be made in future trials. Not like you can plug in two scaffolds and expect better efficacy. This is likely the exact protocol to be tested in the pivotal trial. Efficacy or fail.
    Mar 30, 2015. 03:00 PM | 3 Likes Like |Link to Comment
  • Atossa Genetics: Spotty Track Record And Short On Cash [View article]
    Maybe, but they are low on cash though.
    Feb 26, 2015. 03:06 PM | Likes Like |Link to Comment
  • Pluristem Therapeutics: Questionable Ethics And Bucket Shop Coverage [View article]
    Yup, sounds about right.
    Feb 2, 2015. 05:29 PM | 2 Likes Like |Link to Comment
  • 15 Biotech Names For 2015 [View article]
    April just posted. I think as a result of the BCLI trial and perhaps Jason's article. Either way, a strong individual for dealing with such a terrible disease and I applaud her bravery, trial or not. http://aprilals.com
    Jan 5, 2015. 11:16 PM | 4 Likes Like |Link to Comment
  • 15 Biotech Names For 2015 [View article]
    Joe, is there a medium for which you will be sharing in further correspondence with Jordan?
    Jan 5, 2015. 10:37 PM | 1 Like Like |Link to Comment
  • A Look At BrainStorm Cell Therapeutics' ALS Phase IIa Results [View article]
    I'd disagree with their being no value in the development of an ALS drug that decreases the rate of progression. There are plenty of approved cancer drugs making $millions for their developers that only prolong patient life for a couple of months. We need to keep the patients in mind here.
    Jan 5, 2015. 09:40 PM | 4 Likes Like |Link to Comment
  • Cynapsus Or Acorda - Whose Market Is It For Parkinson's Disease? [View article]
    I believe this to be the problem, Michael. If L-dopa > 600 mg/day causes dyskinesia, then dosing more L-dopa would not be the preferred therapy.
    Nov 26, 2014. 09:51 AM | Likes Like |Link to Comment
  • Cynapsus Offers Potential Big Returns [View article]
    When is uplisting ever bad?
    Nov 25, 2014. 09:48 PM | Likes Like |Link to Comment
  • Cynapsus Or Acorda - Whose Market Is It For Parkinson's Disease? [View article]
    Thanks for your response, Michael. Could you post sources for your data? There are numerous studies more recent than the '90s that reflect the same conclusion as that study I posted.

    http://1.usa.gov/1thMEuZ
    http://1.usa.gov/1thMGD9
    Nov 25, 2014. 09:34 PM | 2 Likes Like |Link to Comment
  • Cynapsus Or Acorda - Whose Market Is It For Parkinson's Disease? [View article]
    Here ya go! Problems with long-term levodopa therapy for Parkinson's disease.

    http://1.usa.gov/1uTYS1q
    Nov 25, 2014. 10:46 AM | 3 Likes Like |Link to Comment
  • Cynapsus Offers Potential Big Returns [View article]
    Needs an update, but certainly seems a whole lot better than 95% losers...

    http://bit.ly/1v7Ri4N
    Aug 5, 2014. 05:00 PM | 3 Likes Like |Link to Comment
  • StemCells, Inc., And Neuralstem, Inc.: A Side-By-Side Analysis [View article]
    STEM is in the middle of a proposed $20M raise, but I think the fundamental story has changed with the conflict of interest issue and now a former employee suing the company claiming they weren't following GMP protocol.

    http://bit.ly/1qiTLay
    http://bit.ly/1rsiwhE
    Jul 17, 2014. 05:38 PM | 1 Like Like |Link to Comment
  • Cynapsus Offers Potential Big Returns [View article]
    BABI,

    Item 3 on your list causes item 2.
    Jun 25, 2014. 10:16 AM | Likes Like |Link to Comment
  • Cynapsus Offers Potential Big Returns [View article]
    Baileysix, what do these people think about the long-term prospects of CVT? Meaning, with 5 years of use, will it be any more efficacious than the injectable form? Medical literature states efficacy drops off after several years of use. Also, TONS of companies receive funding based on moronic concepts, especially in biotech.
    Jun 20, 2014. 09:17 AM | 1 Like Like |Link to Comment
COMMENTS STATS
101 Comments
101 Likes